Skip to content
(Bloomberg) -- Sign up here to receive the Davos Diary, a special daily newsletter that will run from Jan. 20-24.Brian Moynihan took over Bank of America Corp. in chaos.Moynihan inherited a bank that was on the brink of extinction, hobbled by the collapse of the U.S. housing market. It faced lawsuits and public criticism and paid the most fines, $76.1 billion, of any bank from 2009 to 2019, according to the U.S. House Financial Services Committee.Marking his 10 years at the helm this month, the chief executive officer can tout a remarkable turnaround, including a 130% gain in its share price, $88 billion in share buybacks and dividends, and a swing from multibillion-dollar losses to record profits.Moynihan, 60, spoke in a Jan. 9 interview in his 50th floor office overlooking Bryant Park in New York City. Comments have been edited and condensed.How did the company recover from the financial crisis?When I...
Lennar Corporation (NYSE:LEN) stock is about to trade ex-dividend in 4 days time. You can purchase shares before the......
Germany's interior minister is suggesting that his country can't build a 5G mobile network without Chinese tech giant Huawei, at least for now, intervening in an issue that has caused tensions between the U.S. and its allies. Washington has been pressuring its allies to ban Huawei, the world's biggest supplier of telecom gear, from new 5G networks. Germany, however, has decided not to ban Huawei from competing for contracts to build the country’s 5G networks, instead agreeing that companies must meet strict standards, which still could end up excluding the Chinese firm....
Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is......
Global pharmaceutical majors and generic drugmakers chopped by 53% on average prices of some of their off-patent products in the latest bidding round under China's national bulk-buy program, government officials said late on Friday. Beijing has been pushing forward the program where drugmakers have to go through a bidding process and cut prices low enough to be considered over generic copies and be allowed to sell their products at public hospitals via large-volume government procurement. Some global firms such as AstraZeneca and Merck have already cautioned about intensifying price pressures on their mature brands in the world's second largest drug market, as China expands the usage of the program....
Today we are going to look at Alfen N.V. (AMS:ALFEN) to see whether it might be an attractive investment prospect. To......
Chr. Hansen Holding A/S (CPH:CHR) shares fell 3.7% to ø497 in the week since its latest quarterly results. It was a......
